Zepbound Shortage 2026: What's Really Happening and How to Stay on Track
You checked the pharmacy app again this morning. Then you called. Then you thought about calling a second pharmacy across town, because last time your Zepbound refill stalled, it took nearly two weeks and more hold music than you'd like to admit to sort out.
If that sounds familiar, here is the strange part. According to the federal government, there is no Zepbound shortage right now. And yet your pharmacy might still be out of your dose. Both of those things can be true at the same time, and understanding why is the difference between panicking over nothing and knowing exactly what to do next.
The Quick Answer: Is Zepbound Actually in Shortage in 2026?
No, not nationally. The U.S. Food and Drug Administration determined that the tirzepatide injection shortage, which covers both Zepbound and Mounjaro, was resolved on December 19, 2024, after an earlier resolution from October 2024 was challenged in court and reevaluated. As of the FDA's most recent update to its
That federal determination is a national supply and demand judgment. It does not promise that every bottle of every dose sits on every shelf in the country tonight. The FDA has said this directly: patients and prescribers may still see intermittent, localized supply disruptions as products move from the manufacturer through distributors to individual pharmacies. In plain terms, Eli Lilly can make enough tirzepatide to meet national demand, and your specific pharmacy can still be waiting on a shipment.
How Zepbound, Mounjaro, and Tirzepatide Actually Fit Together
Three names get used almost interchangeably online, and it helps to know how they relate to each other.
Tirzepatide is the active ingredient itself, a once-weekly injectable medication that acts on two hormone receptors, GIP and GLP-1, involved in blood sugar control and appetite regulation. Eli Lilly manufactures it under two brand names for two different approved uses.
Mounjaro was approved first, for adults with type 2 diabetes, to improve blood sugar control alongside diet and exercise.
Zepbound is the same molecule, approved later for chronic weight management in adults with obesity, or overweight with a weight-related condition, and, since December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity.
Same drug, same manufacturer, same six dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg), different labels depending on what you're being treated for. That distinction matters later, when we get to insurance, because a plan that won't pay for weight loss may still pay for a covered condition like sleep apnea or diabetes.
A Short Timeline of How We Got Here
The whiplash people feel around this drug makes more sense once you see the sequence laid out.
December 2022: Tirzepatide injection is added to the FDA's drug shortage list as demand outpaces Lilly's manufacturing capacity.
November 2023: Zepbound is approved for chronic weight management.
October 2024: FDA determines the shortage is resolved. Compounding pharmacies challenge the decision in court.
December 19, 2024: After reevaluating the case, FDA reaffirms the shortage is resolved, and separately approves Zepbound for moderate-to-severe obstructive sleep apnea.
February and March 2025: The grace periods letting compounding pharmacies keep making copies of tirzepatide run out. State-licensed pharmacies lose that legal cover on February 18, 2025; larger outsourcing facilities lose it on March 19, 2025.
April 30, 2026: FDA proposes going a step further, formally excluding tirzepatide, along with semaglutide and liraglutide, from the list of substances outsourcing facilities may compound in bulk, even during a future shortage. The public comment period closed June 29, 2026, and a final decision is still pending.
What "Resolved" Actually Changed for Compounded Tirzepatide
While tirzepatide was on the shortage list, pharmacies had real legal room to compound versions of it so patients wouldn't lose access. Once FDA calls a shortage resolved, that room closes fast. Under federal law, a state-licensed pharmacy generally cannot keep compounding a drug that is essentially a copy of a commercially available product once that product is no longer in shortage, and outsourcing facilities face an even tighter version of the same rule.
That is exactly what happened here. With the enforcement grace periods gone since March 2025, compounded tirzepatide is legal only in narrow, individualized circumstances, such as a prescriber documenting a specific clinical reason a patient needs something different from the FDA-approved product, not cost or convenience. The proposal FDA issued in April 2026 would close even more of that door permanently, so a future shortage would not automatically reopen large-scale compounding the way it did back in 2022.
If a compounding source tells you their tirzepatide is legal because of an ongoing shortage, that claim is checkable in about thirty seconds on the FDA's own site, and it's worth checking before you trust it.
Why 12.5 mg and 15 mg Are Still the Hardest Doses to Find
All six approved doses of Zepbound are technically available nationwide, but the top of the ladder, 12.5 mg and 15 mg, tends to be where patients still lose time at the pharmacy counter. These are the doses most people are titrating toward, since they carry the strongest results in Lilly's own clinical trials, patients on 15 mg lost an average of 48 pounds, roughly 21 percent of body weight,
Two practical levers help here. Single-dose vials sometimes move through a different part of the supply chain than prefilled pens, so asking your pharmacy or provider about the vial option can occasionally get you unstuck faster. And Lilly's self-pay channel now carries the full dose range directly, worth knowing about as a backup even if you have insurance.
Pens, Vials, and the LillyDirect Self-Pay Option
Zepbound comes in three physical formats, and which ones are realistically available to you depends on how you're paying.
The single-dose prefilled pen is the version most commercial insurance plans cover and the one your pharmacy bills through your benefits.
The single-dose vial requires manual injection with a syringe and has historically been sold only through Lilly's self-pay channel, LillyDirect, for cash-paying patients.
The multi-dose KwikPen, which holds four weekly doses in a single device, is Lilly's newest option, cleared by FDA and launched for self-pay patients on February 23, 2026. Lilly later expanded self-pay pricing on the KwikPen to major retail pharmacies nationwide, not just through home delivery, so local pharmacy pickup at the same cash price is realistic in many places now.
If you don't have insurance coverage for Zepbound, or your plan excludes weight-loss medication outright, LillyDirect'sSelfPay Journey Program is currently the most affordable direct route to the real, FDA-approved drug. Under Lilly's current pricing, the 2.5 mg starting dose runs $299 a month, the 5 mg dose is $399, and every dose from 7.5 mg through 15 mg is $449 a month, as long as you refill within 45 days of your previous delivery. Miss that window on the higher doses and the price reverts to a higher standard rate until you requalify. For comparison, the list price without any program discount runs well over $1,000 a month, so the self-pay numbers are a genuine discount, not a marketing figure.
Insurance, Prior Authorization, and the Medicare Question
Most commercial insurance plans that do cover Zepbound for weight loss require prior authorization first. Expect your provider to need to document a BMI of 30 or higher, or 27 or higher with a weight-related condition like high blood pressure or type 2 diabetes, along with some history of trying diet and exercise. Coverage still depends heavily on what your specific employer's plan has decided to include, since plan sponsors can and do exclude weight-loss drugs entirely regardless of what the insurer offers other members.
Medicare has historically excluded weight-loss medication by law, covering GLP-1 drugs only when prescribed for a condition Medicare does cover, like diabetes or the sleep apnea indication Zepbound carries. That changes on July 1, 2026, when the Medicare GLP-1 Bridge program launches. Under the Bridge, eligible Medicare Part D enrollees can access the Zepbound KwikPen (not the single-dose vial or pen) for a flat $50 monthly copay, once their provider completes a prior authorization confirming they're using it alongside a diet and lifestyle program. If you're on Medicare and hoping to use this route, it's worth having that conversation with your provider before July 1 rather than after, so the paperwork is already moving once the program opens.
What About Wegovy and Ozempic?
Semaglutide, the active ingredient in Novo Nordisk's Wegovy and Ozempic, went through a nearly identical arc. Its shortage was declared resolved on February 21, 2025, followed by the same kind of compounding wind-down that followed tirzepatide. Novo Nordisk also cut its own self-pay cash prices around the end of 2025, landing most doses of Wegovy and Ozempic close to Zepbound's range.
Semaglutide is not the same molecule as tirzepatide. It acts on one hormone receptor instead of two, and switching between them isn't a same-day decision your pharmacist can make for you. If your prescribed dose of Zepbound genuinely isn't available anywhere nearby and you can't wait, ask your provider whether a semaglutide product is a reasonable temporary or permanent alternative for your specific case. It's a real option, not a downgrade, but it's a different treatment plan that deserves its own conversation rather than a pharmacy-counter substitution.
What to Actually Do If Your Pharmacy Is Out This Week
Check the FDA's Drug Shortages Database yourself before assuming anything. It's public, it's updated regularly, and it will tell you in plain language whether tirzepatide is currently listed.
Call your pharmacy and ask specifically about the vial, not just the pen. Supply chains for the two formats don't always move in sync, and a pharmacy that's out of pens sometimes still has vials in stock.
Ask your provider whether holding at your current dose for one more cycle is clinically reasonable while you wait, rather than assuming you have to restart titration from the bottom. A short gap is usually manageable; a gap of several weeks or more typically does mean restarting at a lower dose, so don't sit on a real supply problem too long before flagging it.
If cost, not stock, is the actual barrier, look at LillyDirect's Self Pay Journey Program directly. It's the manufacturer's own cash-pay channel, it covers every approved dose, and the 45-day refill rule is the only real catch to understand up front.
If you're on Medicare, start the prior authorization conversation with your provider now, ahead of the GLP-1 Bridge program's July 1, 2026 start date, so you're not waiting on paperwork after the fact.
If none of that resolves things quickly, get a provider looking at your case sooner rather than later. A short, focused conversation with someone who can review your history and confirm your options is usually faster than another week of calling pharmacies alone.
Common Questions About the Zepbound Shortage
Is Zepbound currently in shortage?
No. FDA declared the tirzepatide shortage resolved on December 19, 2024, and tirzepatide does not appear on FDA's current shortage list.
Why is my pharmacy still out of stock if there's no shortage?
A national shortage determination and one pharmacy's stock on a given day are two different things. FDA itself acknowledges that local supply disruptions can happen even when national supply is adequate.
Can I still get compounded tirzepatide?
Only in narrow, individualized cases documented by a prescriber. General compounding based on the old shortage no longer applies, and FDA has proposed closing that pathway permanently, even for a future shortage.
What's the cheapest way to get Zepbound without insurance?
LillyDirect's Self Pay Journey Program, Lilly's own cash-pay channel, currently prices doses from $299 to $449 a month depending on strength.
Will Medicare cover Zepbound?
Not historically for weight loss alone, but starting July 1, 2026, the Medicare GLP-1 Bridge program covers the Zepbound KwikPen for eligible Part D enrollees at a $50 monthly copay.
You're Not Failing at This
None of the friction described here reflects your effort or your discipline. It's a supply chain, a federal shortage list, and an insurance system, all moving on their own timelines, rarely in sync with the day you actually need your prescription filled.
Casey Hicks, FNP-BC, the nurse practitioner behind Practical Telehealth, built the platform around exactly this kind of gap: real, licensed review of your case, without a three-week wait to ask a straightforward question about your treatment. If you need someone to look at where you are in your Zepbound plan and confirm your next step, a virtual weight loss consultation with a licensed provider is twenty dollars and does not require insurance.
